<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Lambert-Eaton myasthenic syndrome: Clinical features and diagnosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Lambert-Eaton myasthenic syndrome: Clinical features and diagnosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Lambert-Eaton myasthenic syndrome: Clinical features and diagnosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David H Weinberg, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patrick Y Wen, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeremy M Shefner, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard P Goddeau, Jr, DO, FAHA
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 06, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lambert-Eaton myasthenic syndrome (LEMS) is an uncommon disorder of neuromuscular junction transmission with the primary clinical manifestation of muscle weakness. Knowledge of subtle clinical features and laboratory abnormalities that accompany LEMS permits the early identification of the disorder. Early recognition is particularly important because of its strong association with small cell lung cancer (SCLC). Although LEMS can occur at any point in the course of SCLC, it may serve as a marker for early disease.
        </p>
        <p>
         This topic will review the pathophysiology, clinical features, and diagnosis of LEMS. Treatment and prognosis of LEMS are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5134.html" rel="external">
          "Lambert-Eaton myasthenic syndrome: Treatment and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         LEMS is a disorder of reduced acetylcholine (ACh) release from the presynaptic nerve terminals, despite normal ACh vesicle number, normal ACh presynaptic concentration, and normal postsynaptic ACh receptors. Lambert and Elmqvist, through a series of elegant intracellular muscle recordings, found that patients with what is now called LEMS had the following unique features [
         <a href="#rid1">
          1,2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Normal miniature endplate potential amplitude, demonstrating normal postsynaptic sensitivity to ACh
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Markedly reduced evoked endplate potential amplitude, suggesting a significant reduction in ACh release
        </p>
        <p>
        </p>
        <p>
         ACh release was increased by increasing calcium concentrations but not by potassium-induced membrane depolarization. The identification of normal presynaptic ACh content further supported the concept that LEMS is a disorder of reduced ACh release from the presynaptic nerve terminals [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         The mechanism of LEMS is autoimmunity, with the development of antibodies directed against the voltage-gated calcium channel (VGCC).
        </p>
        <p class="headingAnchor" id="H1965313141">
         <span class="h2">
          Autoimmunity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several lines of evidence support a humoral mechanism of disease in LEMS:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Passive transfer experiments successfully induced calcium channel dysfunction in mice exposed to plasma or immunoglobulin G (IgG) from patients with LEMS. This calcium channel blockade could be overcome with high-frequency repetitive nerve stimulation (RNS) [
         <a href="#rid4">
          4-7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Such antibody exposure in mice induced presynaptic neuromuscular junction morphologic changes similar to those seen in patients with LEMS.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Removal of antibodies utilizing therapeutic plasma exchange and immunosuppressant agents in patients with LEMS has consistently improved both the clinical deficits and the electrophysiologic disease markers [
         <a href="#rid4">
          4,8-10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Voltage-gated calcium channel
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antibodies directed against the VGCC, a large transmembrane protein with multiple subunits, play a central role in the pathophysiology of LEMS. These antibodies interfere with the normal calcium flux required for the release of ACh [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         The alpha-1 subunit of the VGCC contains a central calcium-conducting channel, a voltage sensor, and ligand binding sites. There are many subtypes of mammalian VGCCs, each characterized by the ligand binding characteristics of the alpha-1 subunit. Among these, the L-type, N-type, and P/Q-type VGCC are the most important.
        </p>
        <p>
         P/Q-type VGCCs make up more than 95 percent of the functioning receptors at the neuromuscular junction and probably represent the main immunologic target in LEMS [
         <a href="#rid12">
          12,13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H650632883">
         <span class="h1">
          CLASSIFICATION
         </span>
        </p>
        <p class="headingAnchor" id="H1115480152">
         <span class="h2">
          Paraneoplastic LEMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The expression of functional VGCCs in the surface membrane of small cell lung cancer (SCLC) cells (among numerous other neural antigens) is probably responsible for most if not all cases of paraneoplastic LEMS [
         <a href="#rid14">
          14
         </a>
         ]. Antibodies from patients with LEMS inhibit the function of the VGCCs in the surface of SCLC cells in a dose-dependent fashion, further supporting the relationship [
         <a href="#rid15">
          15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4628.html" rel="external">
          "Pathobiology and staging of small cell carcinoma of the lung"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H230347614">
         <span class="h2">
          Nonparaneoplastic LEMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The specific trigger inducing the development of VGCC antibodies in nonparaneoplastic LEMS is unknown [
         <a href="#rid16">
          16
         </a>
         ]. However, nonparaneoplastic LEMS is associated with underlying immune-mediated diseases [
         <a href="#rid17">
          17,18
         </a>
         ]. One study found that autoimmune disorders, such as type 1 diabetes mellitus or thyroid disorders, occurred in 27 percent of LEMS patients without cancer and 11 percent of those with LEMS and SCLC [
         <a href="#rid17">
          17
         </a>
         ]. Families of patients with nonparaneoplastic LEMS had an increased frequency of autoimmune diseases, with affected family members linked through the maternal line; by contrast, families of patients with paraneoplastic LEMS had no increased frequency of autoimmune diseases. In another study, patients with nonparaneoplastic LEMS had an increased incidence of organ-specific autoantibodies to thyroid, gastric, and/or skeletal muscle compared with controls [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1337574032">
         <span class="h2">
          Toxic LEMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of immune checkpoint inhibitor (ICI) therapy for malignancies has led to the recognition of immune-related adverse events (irAEs) affecting many different organs. Several neuromuscular irAEs have been reported, including myositis, myasthenia gravis, and neuropathies [
         <a href="#rid20">
          20
         </a>
         ]. In addition, case studies have identified an association between ICI therapy and LEMS [
         <a href="#rid21">
          21
         </a>
         ], but it is not yet known if there is a causal relationship [
         <a href="#rid22">
          22
         </a>
         ]. If LEMS develops during ICI therapy, the medication is typically discontinued, and other treatment considerations are pursued. (See
         <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">
          "Toxicities associated with immune checkpoint inhibitors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The true incidence of LEMS is unknown, but the condition is uncommon and occurs much less frequently than myasthenia gravis, the other major disorder of neuromuscular junction transmission. In a population-based study from a region of Holland with 1.7 million inhabitants, 220 cases of myasthenia gravis and 10 of LEMS were identified over a nine-year period; the annual incidence and prevalence of LEMS were 0.5 and 2.3 per million population [
         <a href="#rid23">
          23
         </a>
         ]. A similar prevalence for confirmed cases of LEMS (2.6 per million) was reported in a later population-based study of 12.5 million patients in the United States Veterans Affairs health system [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         Most cases of LEMS occur among middle-aged adults, but LEMS can affect younger and older adults, and rare cases have been reported in children [
         <a href="#rid25">
          25
         </a>
         ]. However, the age of LEMS onset is earlier in patients without cancer (nonparaneoplastic LEMS) compared with those with cancer (paraneoplastic LEMS) [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         Approximately one-half of LEMS cases are associated with a malignancy, mainly small cell lung cancer (SCLC), and less often with lymphoproliferative disorders. (See
         <a class="medical medical_review" href="/z/d/html/5134.html" rel="external">
          "Lambert-Eaton myasthenic syndrome: Treatment and prognosis", section on 'Evaluation for malignancy'
         </a>
         .)
        </p>
        <p>
         The incidence and prevalence of LEMS in patients with SCLC are estimated to be approximately 3 percent [
         <a href="#rid27">
          27,28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with LEMS present with complaints of slowly progressive proximal muscle weakness, and this feature is present in almost all patients at some point in the illness [
         <a href="#rid29">
          29,30
         </a>
         ]. Occasional patients have a subacute or acute presentation. The clinical signs of LEMS parallel the symptoms.
        </p>
        <p>
         Most often, LEMS has a pattern more suggestive of a myopathy than a neuromuscular junction disorder, with slowly progressive proximal lower extremity weakness, distinctive autonomic findings, a smattering of oculobulbar findings, and recovery of lost deep tendon reflexes or improvement in muscle strength with vigorous, brief muscle activation.
        </p>
        <p>
         The paraneoplastic and nonparaneoplastic forms of LEMS have similar signs and symptoms [
         <a href="#rid29">
          29
         </a>
         ]. However, those with an underlying malignancy may experience more rapid progression of neurologic symptoms than those without cancer [
         <a href="#rid26">
          26,31
         </a>
         ].
        </p>
        <p>
         Some patients have combined paraneoplastic cerebellar degeneration and LEMS [
         <a href="#rid32">
          32
         </a>
         ]. In a series of Japanese patients with LEMS, 9 of 65 patients (14 percent) with small cell lung cancer (SCLC) had appendicular ataxia, probably from associated paraneoplastic cerebellar degeneration [
         <a href="#rid33">
          33
         </a>
         ]. All nine patients had high titers of voltage-gated calcium channel (VGCC) antibodies compared with none of the 45 patients without cancer. (See
         <a class="medical medical_review" href="/z/d/html/5188.html" rel="external">
          "Overview of paraneoplastic syndromes of the nervous system"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15822.html" rel="external">
          "Paraneoplastic cerebellar degeneration"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4283891375">
         <span class="h2">
          Muscle weakness
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients typically describe an alteration in gait or difficulty arising from a chair or managing stairs caused by proximal leg weakness. Upper extremity complaints are usually modest and typically involve proximal muscle function. Many describe aching or stiff muscles. Muscle fatigability or cramping is common, particularly after protracted exercise.
        </p>
        <p>
         Proximal limb weakness without significant muscle atrophy is the most frequent finding. The degree of weakness is often less than the functional difficulty would lead one to expect, a discrepancy that sometimes leads to a misdiagnosis of functional neurological symptom disorder (conversion disorder). There tends to be relative preservation of distal muscle function. Deep tendon reflexes are almost always depressed or absent. Ptosis is the most common cranial nerve finding in LEMS; extraocular, pharyngeal, tongue, and neck muscles are less often affected. (See
         <a class="local">
          'Ptosis and cranial nerve involvement'
         </a>
         below.)
        </p>
        <p>
         Compared with patients who have nonparaneoplastic LEMS, patients with paraneoplastic LEMS and SCLC typically have a more rapidly progressive course with a greater degree of weakness involving proximal and distal arm muscles and distal leg muscles [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         Symmetric muscle involvement is the most common pattern in LEMS. However, there are observations of patients presenting with regional weakness (eg, weakness in one area only, such as the proximal legs alone, or weakness isolated to limb, ocular, oropharyngeal, or respiratory muscles) [
         <a href="#rid34">
          34-36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H931002177">
         <span class="h2">
          Postexercise facilitation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recovery of lost deep tendon reflexes or improvement in muscle strength with vigorous, brief muscle activation is a unique aspect of LEMS. Maximal isometric contraction of the relevant muscle for 10 to 15 seconds can sometimes lead to temporary reappearance of previously depressed or absent deep tendon reflexes, and to temporary improvement of muscle weakness. This phenomenon, referred to as postexercise or postactivation facilitation, is often the defining bedside clinical observation and should be part of the routine examination of a patient with proximal muscle weakness or even complaints of weakness, especially when hyporeflexia or areflexia are conjoined. Postexercise or postactivation facilitation are also applied to an increase in compound muscle action potential (CMAP) amplitude that may be seen with repetitive nerve stimulation (RNS) or brief exercise in patients with LEMS. (See
         <a class="local">
          'Electrodiagnostic studies'
         </a>
         below.)
        </p>
        <p>
         Because of possible facilitation after exercise, reflexes and muscle power testing are best performed after a period of rest. More sustained physical activity can often induce muscle weakness (fatigable weakness). At times, this pattern can appear to represent an inconsistent effort on the part of the patient.
        </p>
        <p class="headingAnchor" id="H4154845334">
         <span class="h2">
          Ptosis and cranial nerve involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cranial nerve involvement is present in some patients with LEMS but is typically less severe and less striking than that seen in myasthenia gravis. Ocular symptoms, particularly ptosis and diplopia, are the most common cranial nerve manifestation with LEMS [
         <a href="#rid37">
          37
         </a>
         ]. Excessive or paradoxical eyelid elevation may occur after sustained upgaze in patients with LEMS [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         Initial eye muscle weakness is uncommon in LEMS [
         <a href="#rid39">
          39,40
         </a>
         ], but patients with LEMS can develop prominent ocular or oropharyngeal manifestations during the course of their illness. One retrospective report found initial extraocular muscle weakness occurred in none of the 38 patients with LEMS [
         <a href="#rid39">
          39
         </a>
         ]. In another retrospective series of 23 patients with LEMS, the presenting symptoms were ptosis, diplopia, dysarthria, or dysphagia in seven (30 percent) [
         <a href="#rid41">
          41
         </a>
         ]. During the course of LEMS, ptosis and/or diplopia were noted in 15 patients (65 percent), and dysphagia and/or dysarthria in 12 (52 percent).
        </p>
        <p class="headingAnchor" id="H2883277590">
         <span class="h2">
          Autonomic dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autonomic dysfunction is often present in patients with LEMS and can be an important clue to the diagnosis, though it is rarely a defining feature. Dry mouth from reduced salivation is the most common autonomic symptom and is occasionally the presenting complaint [
         <a href="#rid42">
          42
         </a>
         ]. Symmetric, sluggish pupillary light responses are also common, as is erectile dysfunction in men with LEMS. In a study of autonomic dysfunction in LEMS involving 30 patients, dry mouth was identified in 77 percent of patients, and impotence was present in 45 percent of men [
         <a href="#rid43">
          43
         </a>
         ]. Abnormalities were found in tests of sudomotor function (83 percent), cardiovagal reflexes (75 percent), salivation (44 percent), and adrenergic function (37 percent). Other autonomic symptoms may include blurred vision and constipation.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Respiratory failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although most patients with LEMS do not have significant diaphragmatic involvement, particularly in the early stages of the illness, respiratory failure can occur late in the course [
         <a href="#rid44">
          44-47
         </a>
         ]. Thus, LEMS must be considered in the differential diagnosis of patients presenting with neuromuscular respiratory failure.
        </p>
        <p>
         Even in patients without respiratory symptoms, detailed investigations into respiratory muscle function with transdiaphragmatic pressure recording, sustained inspiratory force measurements, and phrenic nerve stimulation may reveal mild to moderate respiratory weakness [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1780066161">
         <span class="h1">
          EVALUATION AND DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of LEMS deserves careful consideration for any patient who presents with proximal muscle weakness. The collection of limb weakness, dry mouth, hyporeflexia, and any combination of oropharyngeal muscle weakness or ptosis should strongly suggest the diagnosis. A significant degree of clinical suspicion is necessary to recognize the atypical patient with LEMS, such as those who present with isolated respiratory insufficiency or regional weakness isolated to limb, ocular, or oropharyngeal muscles.
        </p>
        <p class="headingAnchor" id="H692195893">
         <span class="h2">
          Confirming the diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with suspected LEMS should have electrodiagnostic studies, including repetitive nerve stimulation (RNS), and anti-P/Q-type voltage-gated calcium channel (VGCC) antibody testing to confirm the diagnosis.
        </p>
        <p>
         The diagnosis of LEMS is confirmed on high-frequency RNS by a reproducible postexercise increase in compound muscle action potential (CMAP) amplitude of at least 100 percent compared with pre-exercise baseline value (see
         <a class="local">
          'Repetitive nerve stimulation and exercise testing'
         </a>
         below). A high titer P/Q-type VGCC antibody result is strongly suggestive of LEMS in the appropriate clinical setting (see
         <a class="local">
          'VGCC antibody testing'
         </a>
         below). However, P/Q-type VGCC antibodies are present in a variety of clinical situations where LEMS is not present. If these studies are not definitive, single-fiber electromyography (SFEMG) can be diagnostic for a neuromuscular junction disorder but is less specific for LEMS than the above studies. (See
         <a class="local">
          'Single-fiber electromyography'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1145395837">
         <span class="h2">
          Electrodiagnostic studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         The electrodiagnostic evaluation of suspected LEMS typically involves the following elements [
         <a href="#rid48">
          48
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Routine motor and sensory nerve conduction studies (NCS)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High-frequency RNS and/or exercise testing
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Needle electromyography (EMG)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         SFEMG for selected patients only
        </p>
        <p>
        </p>
        <p>
         All patients suspected of LEMS require a routine set of NCS and a conventional EMG in addition to either a postexercise motor nerve test or a high-frequency RNS test. SFEMG is reserved for the occasional patient where the diagnosis remains in doubt following these more conventional procedures. SFEMG is very sensitive for a neuromuscular junction disorder but not as specific for a presynaptic localization.
        </p>
        <p class="headingAnchor" id="H1191569971">
         <span class="h3">
          Motor and sensory nerve conduction studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         The CMAP of resting muscle in patients with LEMS usually has a significantly reduced baseline amplitude [
         <a href="#rid49">
          49
         </a>
         ]. In fact, the presence of unexpectedly low motor amplitudes, especially with normal sensory amplitudes, should suggest the possibility of a presynaptic neuromuscular junction disorder. At times, excessive variability in maximum CMAP amplitude from stimulus to stimulus should be a hint to consider LEMS as well. In patients with LEMS, distal latencies and conduction velocities are normal.
        </p>
        <p>
         Occasionally, an electrophysiologist makes the diagnosis of LEMS when it was not suspected clinically on the basis of isolated low CMAP amplitudes. For patients with low or borderline-low CMAP amplitudes at rest, repeating the motor nerve conduction distal motor stimulation after 10 seconds of maximal exercise is recommended to look for postexercise facilitation of the CMAP amplitude, which is a characteristic finding in LEMS [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H189349519">
         <span class="h3">
          Repetitive nerve stimulation and exercise testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         During high-frequency (10 to 50 Hz) RNS  (
         <a class="graphic graphic_waveform graphicRef58848" href="/z/d/graphic/58848.html" rel="external">
          waveform 1
         </a>
         ) or after brief (eg, 10 seconds) maximal isometric muscle activation  (
         <a class="graphic graphic_waveform graphicRef66509" href="/z/d/graphic/66509.html" rel="external">
          waveform 2
         </a>
         ), patients with LEMS typically have a significant increment with a marked increase in the CMAP amplitude. The increase in the CMAP amplitude with high-frequency stimulation is referred to as postactivation facilitation, and the increase in CMAP amplitude after brief isometric exercise (compared with the baseline pre-exercise CMAP amplitude) is called postexercise facilitation.
        </p>
        <p>
         An increase in the CMAP amplitude &gt;100 percent after exercise or with high-frequency RNS is considered diagnostic of a presynaptic neuromuscular junction disorder [
         <a href="#rid50">
          50,51
         </a>
         ], and the increase is frequently even greater. However, some studies have found that a significant number of patients have increments with RNS below 100 percent [
         <a href="#rid52">
          52-54
         </a>
         ]; thus, increments of 60 to 99 percent are strongly supportive of a presynaptic neuromuscular junction disorder. One study of 156 patients undergoing evaluation for LEMS showed an increased electrodiagnostic sensitivity of 78 percent compared with 59 percent without loss of specificity when using an incremental threshold of 60 percent [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
         The high-frequency RNS test may be more sensitive than the postexercise facilitation test for the diagnosis of LEMS, but evidence is equivocal, and the high-frequency RNS test is painful [
         <a href="#rid54">
          54,56,57
         </a>
         ]. Most experts favor using the 10 second exercise test first because it is simple and better tolerated [
         <a href="#rid58">
          58
         </a>
         ]. However, when there is a strong level of clinical suspicion for LEMS, the high-frequency RNS test is indicated for patients who do not show a diagnostic incremental increase in CMAP amplitude after the exercise test. It is also indicated for those unable to cooperate with intense voluntary muscle activation.
        </p>
        <p class="headingAnchor" id="H2421364927">
         <span class="h3">
          Needle electromyography
         </span>
         <span class="headingEndMark">
          —
         </span>
         Needle EMG is usually normal in LEMS [
         <a href="#rid48">
          48
         </a>
         ]. However, in some cases the motor unit action potentials are unstable, and uncommonly they can be small (low amplitude), polyphasic, and short in duration, mimicking a myopathy [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1053200390">
         <span class="h3">
          Single-fiber electromyography
         </span>
         <span class="headingEndMark">
          —
         </span>
         SFEMG in LEMS often shows significant jitter and transmission blocking that is characteristically improved at higher firing rates [
         <a href="#rid60">
          60-62
         </a>
         ]. SFEMG is more sensitive than RNS for the diagnosis of neuromuscular junction disorders but is less specific and cannot definitively distinguish between LEMS and myasthenia gravis. SFEMG is also less widely available than RNS, which is therefore the preferred initial test [
         <a href="#rid50">
          50,51
         </a>
         ]. However, when RNS is normal in patients with a high suspicion of a neuromuscular junction disorder, SFEMG of at least one symptomatic muscle should be performed and, if one muscle is normal, a second muscle can be studied. (See
         <a class="medical medical_review" href="/z/d/html/14147.html" rel="external">
          "Electrodiagnostic evaluation of the neuromuscular junction", section on 'Single-fiber electromyography'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          VGCC antibody testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antibodies against the P/Q-type VGCC are present in approximately 85 to 95 percent of patients with LEMS [
         <a href="#rid11">
          11,33,63
         </a>
         ], and radioimmunoassay for these antibodies is the preferred serologic test. While the anti-P/Q-type VGCC antibody test is confirmatory in patients who otherwise have clinical and electrophysiologic features of LEMS, the antibody test alone is not diagnostic, especially in the presence of a malignancy or amyotrophic lateral sclerosis.
        </p>
        <p>
         There is a low frequency of P/Q-type VGCC antibodies in healthy control patients, in patients with myasthenia gravis, and in patients with other autoimmune diseases, confirming the high specificity of the test when there is a high pretest probability of LEMS [
         <a href="#rid63">
          63
         </a>
         ]. However, low titer VGCC antibodies have been detected in several groups of patients, including those with other neurologic paraneoplastic disorders, those who have cancer without neurologic signs or symptoms, and those with amyotrophic lateral sclerosis.
        </p>
        <p>
         Test performance was evaluated in a series of 65 patients with LEMS [
         <a href="#rid63">
          63
         </a>
         ]. High titer anti-P/Q-type VGCC antibodies were present in 62 patients (95 percent), including all 32 with a diagnosis of cancer. Lower titer anti-P/Q-type and anti-N-type VGCC antibodies were also present in 38 of 70 patients (54 percent) who had lung, ovarian, or breast carcinoma and paraneoplastic complications other than LEMS; in 22 of 90 patients (24 percent) who had cancer without overt neurologic complications; in 18 of 78 patients (23 percent) who had sporadic amyotrophic lateral sclerosis; and in 2 of 69 patients (3 percent) who had myasthenia gravis, epilepsy, or scleroderma.
        </p>
        <p>
         While P/Q-type VGCC antibodies are specific for LEMS, there is no established clinical utility for other VGCC antibodies that are sometimes associated with LEMS. Antibodies to the N-type VGCC are found in approximately 30 to 40 percent of patients with LEMS, and there is some evidence to suggest that the presence of these antibodies increases the likelihood of small cell lung cancer (SCLC). Furthermore, one study raised the possibility that antibodies directed against domain IV of the alpha-1 subunit of P/Q-type VGCC are more common in the nontumor LEMS cases [
         <a href="#rid64">
          64
         </a>
         ]. More data are needed to determine if this will be a clinically useful observation.
        </p>
        <p class="headingAnchor" id="H170763918">
         <span class="h2">
          Evaluation for malignancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The aggressive search for a primary underlying malignancy is central to the management of patients with LEMS; SCLC is the most common associated tumor in patients with LEMS. This issue is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5134.html" rel="external">
          "Lambert-Eaton myasthenic syndrome: Treatment and prognosis", section on 'Evaluation for malignancy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of LEMS varies by symptom presentation. Conditions that present with progressive muscle weakness are most commonly implicated, particularly myasthenia gravis, inflammatory muscle disease, limb-girdle muscular dystrophy (LGMD), and motor neuron disease. (See
         <a class="local">
          'Progressive muscle weakness'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1874500038">
         <span class="h2">
          Progressive muscle weakness
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myasthenia gravis
         </strong>
         – LEMS has distinct differences from the symptoms and signs seen with myasthenia gravis, which is the most common clinical disorder of neuromuscular junction transmission. LEMS usually presents with slowly progressive proximal leg weakness and difficulty walking, while ocular and bulbar muscles are typically less prominently involved. Myasthenia gravis characteristically presents with fluctuating ocular or bulbar weakness and less often with constant and progressive skeletal muscle weakness. (See
         <a class="medical medical_review" href="/z/d/html/5170.html" rel="external">
          "Clinical manifestations of myasthenia gravis", section on 'Clinical features'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5168.html" rel="external">
          "Differential diagnosis of myasthenia gravis", section on 'Lambert-Eaton myasthenic syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A study comparing the clinical features of 38 patients with LEMS and 101 patients with myasthenia gravis confirmed the marked contrast in their presentations [
         <a href="#rid39">
          39
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Initial limb weakness occurred in 95 percent of patients with LEMS compared with 12 percent of patients with myasthenia gravis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Initial extraocular muscle weakness occurred in none of the patients with LEMS compared with 59 percent of patients with myasthenia gravis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Both groups infrequently presented with oropharyngeal muscle weakness (5 and 12 percent for LEMS and myasthenia gravis, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         At the point of maximum severity, no patient with LEMS had weakness restricted to extraocular muscles, oropharyngeal muscles, or arms. All patients with LEMS had leg weakness. By contrast, weakness in patients with myasthenia gravis was purely ocular in 25 percent, purely ocular and oropharyngeal in 5 percent, and restricted to the arms as the only limb manifestation in 12 percent. These findings suggest that LEMS is unlikely in patients with limb weakness confined to the arms [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Of note, patients with LEMS usually have significant symptoms and abnormalities on electrodiagnostic studies that can be out of proportion to the less pronounced weakness found on examination, while patients with myasthenia gravis usually have rather significant weakness and fatigability in contrast to modest abnormalities on electrodiagnostic studies [
         <a href="#rid65">
          65,66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         At the bedside, pronounced eyelid elevation may occur after sustained upgaze in patients with LEMS [
         <a href="#rid38">
          38
         </a>
         ]. This finding is in contradistinction to the fatigable ptosis commonly seen in patients with myasthenia gravis during the same maneuver. The ice pack test can also be useful to support the diagnosis of myasthenia gravis, but the diagnosis is typically confirmed by immunologic and/or electrodiagnostic studies. The diagnosis of myasthenia gravis is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5170.html" rel="external">
          "Clinical manifestations of myasthenia gravis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5130.html" rel="external">
          "Diagnosis of myasthenia gravis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The coexistence of LEMS and myasthenia gravis was first reported in two patients who were seropositive for both voltage-gated calcium channel (VGCC) antibodies and acetylcholine receptor (AChR) antibodies [
         <a href="#rid67">
          67
         </a>
         ]. Subsequent data suggest that only rare patients have the clinical, immunologic, and electrophysiologic features of both disorders [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inflammatory muscle disease
         </strong>
         – The most common clinical presentation of LEMS, that of slowly progressive, symmetric proximal muscle weakness, can suggest inflammatory muscle disease, including polymyositis, dermatomyositis, or inclusion body myositis. However, deep tendon reflexes are preserved in myopathies, but absent in LEMS unless activated by exercise. Myalgias are common with myopathies, and patients with dermatomyositis may also have associated skin findings. (See
         <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">
          "Clinical manifestations of dermatomyositis and polymyositis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5163.html" rel="external">
          "Clinical manifestations and diagnosis of inclusion body myositis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Limb-girdle muscular dystrophy (LGMD)
         </strong>
         – Patients with LGMD typically present with proximal weakness. Weakness in LGMD may also be accompanied by muscle atrophy, an uncommon feature in LEMS. Electromyography shows myopathic changes in LGMD but is typically normal in LEMS. (See
         <a class="medical medical_review" href="/z/d/html/6190.html" rel="external">
          "Limb-girdle muscular dystrophy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Motor neuron disease
         </strong>
         – Motor neuron disease (eg, amyotrophic lateral sclerosis), a motor neuropathy, myasthenia gravis, or a myelopathy are less likely alternatives. These conditions can be distinguished from LEMS on clinical and electrodiagnostic grounds:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Amyotrophic lateral sclerosis
         </strong>
         typically presents with asymmetric limb weakness or bulbar weakness with dysarthria or dysphagia, usually with a combination of upper motor neuron and lower motor neuron symptoms and signs. The electrodiagnostic findings in amyotrophic lateral sclerosis combine features of acute and chronic denervation and reinnervation, which are not present in LEMS. (See
         <a class="medical medical_review" href="/z/d/html/5136.html" rel="external">
          "Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5138.html" rel="external">
          "Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Multifocal motor neuropathy
         </strong>
         typically presents with the subacute onset of progressive asymmetric arm and hand weakness and lower motor neuron signs. There are no upper motor neuron signs, and no bulbar involvement or sensory loss. The neuronal involvement is most often patchy, with some nerves unaffected and others severely involved. Motor nerve conduction studies (NCS) usually show evidence of focal demyelination and conduction block. Sensory conduction through the same segment of nerve is normal. Elevated titers of anti-GM1 antibodies are present in 30 to 80 percent of patients. (See
         <a class="medical medical_review" href="/z/d/html/89904.html" rel="external">
          "Multifocal motor neuropathy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Peripheral nerve disorders
         </strong>
         – Several peripheral nerve disorders such as polyneuropathy or polyradiculopathy may present with diffuse or multifocal weakness, similar to weakness in LEMS. However, these conditions do not feature postexercise facilitation. In addition, the sensory components seen with polyneuropathy or polyradiculopathy clearly distinguish those disorders from LEMS in most cases. (See
         <a class="medical medical_review" href="/z/d/html/5284.html" rel="external">
          "Overview of polyneuropathy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14149.html" rel="external">
          "Polyradiculopathy: Spinal stenosis, infectious, carcinomatous, and inflammatory nerve root syndromes"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Neurologic manifestations of Sjögren's disease are protean and may include muscle weakness. Dry mouth may suggest Sjögren's disease when it is a prominent symptom early in the course of LEMS. (See
         <a class="medical medical_review" href="/z/d/html/5607.html" rel="external">
          "Clinical manifestations of Sjögren's disease: Exocrine gland disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3848188402">
         <span class="h2">
          Cranial nerve deficits
         </span>
         <span class="headingEndMark">
          —
         </span>
         When cranial nerve abnormalities are present or prominent, the main consideration in the differential diagnosis of LEMS is myasthenia gravis (see
         <a class="local">
          'Progressive muscle weakness'
         </a>
         above). Multiple cranial mononeuropathies or at times a meningeal-based disease also need to be considered, but the pure motor nature of LEMS makes these distinctions fairly clear.
        </p>
        <p class="headingAnchor" id="H541723337">
         <span class="h2">
          Respiratory failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Isolated respiratory failure is an uncommon or late-appearing feature in LEMS, typically associated with other neurologic symptoms. For the unusual presentation of fairly isolated respiratory failure, the differential diagnosis includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Motor neuron disease (See
         <a class="medical medical_review" href="/z/d/html/5136.html" rel="external">
          "Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Myasthenia gravis (See
         <a class="medical medical_review" href="/z/d/html/5170.html" rel="external">
          "Clinical manifestations of myasthenia gravis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acid maltase deficiency (See
         <a class="medical medical_review" href="/z/d/html/2905.html" rel="external">
          "Lysosomal acid alpha-glucosidase deficiency (Pompe disease, glycogen storage disease II, acid maltase deficiency)"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Polymyositis (See
         <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">
          "Clinical manifestations of dermatomyositis and polymyositis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and pathophysiology
         </strong>
         – Lambert-Eaton myasthenic syndrome (LEMS) is an uncommon disorder of neuromuscular junction transmission in which the primary clinical manifestation is muscle weakness. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Pathophysiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Antibodies directed against the voltage-gated calcium channel (VGCC) interfere with the normal calcium flux and reduce acetylcholine release from the presynaptic nerve terminals.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The autoimmunity in LEMS may be paraneoplastic, occurring mainly in patients with small cell lung cancer (SCLC), or nonparaneoplastic, occurring typically in those with underlying immune-mediated conditions or receiving immunosuppression therapies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – The incidence of LEMS is unknown, but the condition is rare. Most cases of LEMS occur among middle-aged adults, but LEMS can affect younger and older adults, and rare cases have been reported in children. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Approximately one-half of LEMS cases are associated with a malignancy, mainly SCLC. The age of LEMS onset is earlier in patients with nonparaneoplastic LEMS compared with those with cancer (paraneoplastic LEMS).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – Most patients with LEMS present with slowly progressive proximal muscle weakness, particularly involving the legs. Deep tendon reflexes are typically depressed or absent. Ocular symptoms, especially ptosis and diplopia, or bulbar muscle weakness may occur with LEMS but are rarely the presenting or dominant feature of the illness. Most patients do not have significant respiratory muscle weakness, but respiratory failure may occur late in the course. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Recovery of lost deep tendon reflexes or improvement in muscle strength with vigorous, brief muscle activation is a unique aspect of LEMS.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of LEMS is usually made clinically. Confirmatory evidence on electrodiagnostic studies includes a reproducible postexercise increase in compound muscle action potential amplitude of at least 60 percent compared with pre-exercise baseline value or a similar increment on high-frequency repetitive nerve stimulation without exercise. A high titer P/Q-type VGCC antibody is also strongly suggestive of LEMS in the appropriate clinical setting. (See
         <a class="local">
          'Evaluation and diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The differential diagnosis of LEMS typically includes conditions that present with progressive muscle weakness, particularly myasthenia gravis, inflammatory muscle disease, limb-girdle muscular dystrophy, and motor neuron disease. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients who present with prominent cranial nerve deficits, myasthenia gravis, multiple cranial mononeuropathies, and meningeal-based disease should be considered. Isolated respiratory failure may also be due to conditions such as motor neuron disease, myasthenia gravis, acid maltase deficiency, or polymyositis.
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Lambert EH, Elmqvist D. Quantal components of end-plate potentials in the myasthenic syndrome. Ann N Y Acad Sci 1971; 183:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elmqvist D, Lambert EH. Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma. Mayo Clin Proc 1968; 43:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molenaar PC, Newsom-Davis J, Polak RL, Vincent A. Eaton-Lambert syndrome: acetylcholine and choline acetyltransferase in skeletal muscle. Neurology 1982; 32:1061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lang B, Newsom-Davis J, Wray D, et al. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet 1981; 2:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim YI. Passive transfer of the Lambert-Eaton myasthenic syndrome: neuromuscular transmission in mice injected with plasma. Muscle Nerve 1985; 8:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim YI. Passively transferred Lambert-Eaton syndrome in mice receiving purified IgG. Muscle Nerve 1986; 9:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim YI, Sanders DB, Johns TR, et al. Lambert-Eaton myasthenic syndrome: the lack of short-term in vitro effects of serum factors on neuromuscular transmission. J Neurol Sci 1988; 87:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dau PC, Denys EH. Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome. Ann Neurol 1982; 11:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 1984; 34:480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motomura M, Hamasaki S, Nakane S, et al. Apheresis treatment in Lambert-Eaton myasthenic syndrome. Ther Apher 2000; 4:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motomura M, Johnston I, Lang B, et al. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1995; 58:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lang B, Pinto A, Giovannini F, et al. Pathogenic autoantibodies in the lambert-eaton myasthenic syndrome. Ann N Y Acad Sci 2003; 998:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinto A, Gillard S, Moss F, et al. Human autoantibodies specific for the alpha1A calcium channel subunit reduce both P-type and Q-type calcium currents in cerebellar neurons. Proc Natl Acad Sci U S A 1998; 95:8328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benatar M, Blaes F, Johnston I, et al. Presynaptic neuronal antigens expressed by a small cell lung carcinoma cell line. J Neuroimmunol 2001; 113:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lang B, Vincent A, Murray NM, Newsom-Davis J. Lambert-Eaton myasthenic syndrome: immunoglobulin G inhibition of Ca2+ flux in tumor cells correlates with disease severity. Ann Neurol 1989; 25:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schoser B, Eymard B, Datt J, Mantegazza R. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer. J Neurol 2017; 264:1854.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wirtz PW, Bradshaw J, Wintzen AR, Verschuuren JJ. Associated autoimmune diseases in patients with the Lambert-Eaton myasthenic syndrome and their families. J Neurol 2004; 251:1255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wirtz PW, Smallegange TM, Wintzen AR, Verschuuren JJ. Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg 2002; 104:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lennon VA, Lambert EH, Whittingham S, Fairbanks V. Autoimmunity in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1982; 5:S21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Psimaras D, Velasco R, Birzu C, et al. Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment. J Peripher Nerv Syst 2019; 24 Suppl 2:S74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson CJ, Guidon AC, Khan FB, et al. Case Report of Lambert Eaton Myasthenic Syndrome in a Patient with Small Cell Lung Cancer on Immune Checkpoint Inhibitor Therapy. OBM Neurobiology 2021; 5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seligman C, Chang YM, Luo J, Garden OA. Exploring the role of immune checkpoint inhibitors in the etiology of myasthenia gravis and Lambert-Eaton myasthenic syndrome: A systematic review. Front Neurol 2022; 13:1004810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wirtz PW, Nijnuis MG, Sotodeh M, et al. The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. J Neurol 2003; 250:698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abenroth DC, Smith AG, Greenlee JE, et al. Lambert-Eaton myasthenic syndrome: Epidemiology and therapeutic response in the national veterans affairs population. Muscle Nerve 2017; 56:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hajjar M, Markowitz J, Darras BT, et al. Lambert-Eaton syndrome, an unrecognized treatable pediatric neuromuscular disorder: three patients and literature review. Pediatr Neurol 2014; 50:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wirtz PW, Wintzen AR, Verschuuren JJ. Lambert-Eaton myasthenic syndrome has a more progressive course in patients with lung cancer. Muscle Nerve 2005; 32:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elrington GM, Murray NM, Spiro SG, Newsom-Davis J. Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients. J Neurol Neurosurg Psychiatry 1991; 54:764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Payne M, Bradbury P, Lang B, et al. Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer. J Thorac Oncol 2010; 5:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988; 111 ( Pt 3):577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           EATON LM, LAMBERT EH. Electromyography and electric stimulation of nerves in diseases of motor unit; observations on myasthenic syndrome associated with malignant tumors. J Am Med Assoc 1957; 163:1117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Titulaer MJ, Wirtz PW, Kuks JB, et al. The Lambert-Eaton myasthenic syndrome 1988-2008: a clinical picture in 97 patients. J Neuroimmunol 2008; 201-202:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mason WP, Graus F, Lang B, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 1997; 120 ( Pt 8):1279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakao YK, Motomura M, Fukudome T, et al. Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology 2002; 59:1773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Payne S, Wilkins D, Howard R. An unusual cause of dysphagia. J Neurol Neurosurg Psychiatry 2005; 76:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guruprakash GH, Ahmed I, Shadchehr A. Prostatic carcinoma. Report of a case presenting with dysphagia due to Eaton-Lambert syndrome. J Kans Med Soc 1982; 83:617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiang JR, Shih JY, Wang HC, et al. Small-cell lung cancer presenting with Lambert-Eaton myasthenic syndrome and respiratory failure. J Formos Med Assoc 2002; 101:871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young JD, Leavitt JA. Lambert-Eaton Myasthenic Syndrome: Ocular Signs and Symptoms. J Neuroophthalmol 2016; 36:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breen LA, Gutmann L, Brick JF, Riggs JR. Paradoxical lid elevation with sustained upgaze: a sign of Lambert-Eaton syndrome. Muscle Nerve 1991; 14:863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wirtz PW, Sotodeh M, Nijnuis M, et al. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2002; 73:766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rudnicki SA. Lambert-Eaton myasthenic syndrome with pure ocular weakness. Neurology 2007; 68:1863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burns TM, Russell JA, LaChance DH, Jones HR. Oculobulbar involvement is typical with Lambert-Eaton myasthenic syndrome. Ann Neurol 2003; 53:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark CV, Newsom-Davis J, Sanders MD. Ocular autonomic nerve function in Lambert-Eaton myasthenic syndrome. Eye (Lond) 1990; 4 ( Pt 3):473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Suilleabhain P, Low PA, Lennon VA. Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates. Neurology 1998; 50:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laroche CM, Mier AK, Spiro SG, et al. Respiratory muscle weakness in the Lambert-Eaton myasthenic syndrome. Thorax 1989; 44:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barr CW, Claussen G, Thomas D, et al. Primary respiratory failure as the presenting symptom in Lambert-Eaton myasthenic syndrome. Muscle Nerve 1993; 16:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicolle MW, Stewart DJ, Remtulla H, et al. Lambert-Eaton myasthenic syndrome presenting with severe respiratory failure. Muscle Nerve 1996; 19:1328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beydoun SR. Delayed diagnosis of Lambert-Eaton myasthenic syndrome in a patient presenting with recurrent refractory respiratory failure. Muscle Nerve 1994; 17:689.
          </a>
         </li>
         <li class="breakAll">
          Preston DC, Shapiro BE. Neuromuscular junction disorders. In: Electromyography and neuromuscular disorders: Clinical-electrophysiologic correlations, 3rd ed, Elsevier, 2013. p.529.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oh SJ, Kim DE, Kuruoglu R, et al. Electrophysiological and clinical correlations in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1996; 19:903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement. Muscle Nerve 2001; 24:1236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome. Muscle Nerve 2001; 24:1239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment. Neurology 2000; 54:2176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oh SJ. Diverse electrophysiological spectrum of the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1989; 12:464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oh SJ, Kurokawa K, Claussen GC, Ryan HF Jr. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve 2005; 32:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lipka AF, Titulaer MJ, Tannemaat MR, Verschuuren JJGM. Lowering the cutoff value for increment increases the sensitivity for the diagnosis of Lambert-Eaton myasthenic syndrome. Muscle Nerve 2020; 62:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bady B, Truffert A, Brechard M, et al. [Electrophysiologic data on myasthenic syndromes of the Lambert-Eaton type. A series of 23 cases]. Neurophysiol Clin 1992; 22:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tim RW, Sanders DB. Repetitive nerve stimulation studies in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1994; 17:995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hatanaka Y, Oh SJ. Ten-second exercise is superior to 30-second exercise for post-exercise facilitation in diagnosing Lambert-Eaton myasthenic syndrome. Muscle Nerve 2008; 37:572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crone C, Christiansen I, Vissing J. Myopathic EMG findings and type II muscle fiber atrophy in patients with Lambert-Eaton myasthenic syndrome. Clin Neurophysiol 2013; 124:1889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trontelj JV, Stålberg E. Single motor end-plates in myasthenia gravis and LEMS at different firing rates. Muscle Nerve 1991; 14:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaudhry V, Watson DF, Bird SJ, Cornblath DR. Stimulated single-fiber electromyography in Lambert-Eaton myasthenic syndrome. Muscle Nerve 1991; 14:1227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oh SJ, Ohira M. Single-fiber EMG and clinical correlation in Lambert-Eaton myasthenic syndrome. Muscle Nerve 2013; 47:664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995; 332:1467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pellkofer HL, Armbruster L, Krumbholz M, et al. Lambert-eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel. J Neuroimmunol 2008; 204:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim YI. Lambert-Eaton myasthenic syndrome: evidence for calcium channel blockade. Ann N Y Acad Sci 1987; 505:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanders DB, Guptill JT. Myasthenia gravis and Lambert-Eaton myasthenic syndrome. Continuum (Minneap Minn) 2014; 20:1413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newsom-Davis J, Leys K, Vincent A, et al. Immunological evidence for the co-existence of the Lambert-Eaton myasthenic syndrome and myasthenia gravis in two patients. J Neurol Neurosurg Psychiatry 1991; 54:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oh SJ. Myasthenia gravis Lambert-Eaton overlap syndrome. Muscle Nerve 2016; 53:20.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5174 Version 30.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4330759" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Quantal components of end-plate potentials in the myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4304169" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6287358" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Eaton-Lambert syndrome: acetylcholine and choline acetyltransferase in skeletal muscle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6114283" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2997605" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Passive transfer of the Lambert-Eaton myasthenic syndrome: neuromuscular transmission in mice injected with plasma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3016532" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Passively transferred Lambert-Eaton syndrome in mice receiving purified IgG.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2848093" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Lambert-Eaton myasthenic syndrome: the lack of short-term in vitro effects of serum factors on neuromuscular transmission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7114807" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6322050" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10975475" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Apheresis treatment in Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7823075" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : An improved diagnostic assay for Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14592874" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Pathogenic autoantibodies in the lambert-eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9653186" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Human autoantibodies specific for the alpha1A calcium channel subunit reduce both P-type and Q-type calcium currents in cerebellar neurons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11137587" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Presynaptic neuronal antigens expressed by a small cell lung carcinoma cell line.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2543262" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Lambert-Eaton myasthenic syndrome: immunoglobulin G inhibition of Ca2+ flux in tumor cells correlates with disease severity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28608304" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15503107" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Associated autoimmune diseases in patients with the Lambert-Eaton myasthenic syndrome and their families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12140105" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6302494" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Autoimmunity in the Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31393660" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Case Report of Lambert Eaton Myasthenic Syndrome in a Patient with Small Cell Lung Cancer on Immune Checkpoint Inhibitor Therapy
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36698907" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Exploring the role of immune checkpoint inhibitors in the etiology of myasthenia gravis and Lambert-Eaton myasthenic syndrome: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12796832" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27997683" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Lambert-Eaton myasthenic syndrome: Epidemiology and therapeutic response in the national veterans affairs population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24138947" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Lambert-Eaton syndrome, an unrecognized treatable pediatric neuromuscular disorder: three patients and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15793845" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Lambert-Eaton myasthenic syndrome has a more progressive course in patients with lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1659614" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19934775" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2838124" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The Lambert-Eaton myasthenic syndrome. A review of 50 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13405774" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Electromyography and electric stimulation of nerves in diseases of motor unit; observations on myasthenic syndrome associated with malignant tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18644631" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The Lambert-Eaton myasthenic syndrome 1988-2008: a clinical picture in 97 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9278623" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12473768" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15608023" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : An unusual cause of dysphagia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7153634" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Prostatic carcinoma. Report of a case presenting with dysphagia due to Eaton-Lambert syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12632823" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Small-cell lung cancer presenting with Lambert-Eaton myasthenic syndrome and respiratory failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25993122" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Lambert-Eaton Myasthenic Syndrome: Ocular Signs and Symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1922182" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Paradoxical lid elevation with sustained upgaze: a sign of Lambert-Eaton syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12438488" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17515551" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Lambert-Eaton myasthenic syndrome with pure ocular weakness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12557298" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Oculobulbar involvement is typical with Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2209912" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Ocular autonomic nerve function in Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9443463" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2595631" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Respiratory muscle weakness in the Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8505927" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Primary respiratory failure as the presenting symptom in Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8808659" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Lambert-Eaton myasthenic syndrome presenting with severe respiratory failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8196717" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Delayed diagnosis of Lambert-Eaton myasthenic syndrome in a patient presenting with recurrent refractory respiratory failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8196717" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Delayed diagnosis of Lambert-Eaton myasthenic syndrome in a patient presenting with recurrent refractory respiratory failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8965847" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Electrophysiological and clinical correlations in the Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11494280" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11494281" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10851390" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2725573" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Diverse electrophysiological spectrum of the Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16003742" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32291768" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Lowering the cutoff value for increment increases the sensitivity for the diagnosis of Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1588900" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : [Electrophysiologic data on myasthenic syndromes of the Lambert-Eaton type. A series of 23 cases].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8065402" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Repetitive nerve stimulation studies in the Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18288711" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Ten-second exercise is superior to 30-second exercise for post-exercise facilitation in diagnosing Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23643575" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Myopathic EMG findings and type II muscle fiber atrophy in patients with Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1645844" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Single motor end-plates in myasthenia gravis and LEMS at different firing rates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1662773" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Stimulated single-fiber electromyography in Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23505075" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Single-fiber EMG and clinical correlation in Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7739683" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18809213" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Lambert-eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2446555" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Lambert-Eaton myasthenic syndrome: evidence for calcium channel blockade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25299290" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Myasthenia gravis and Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1650816" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Immunological evidence for the co-existence of the Lambert-Eaton myasthenic syndrome and myasthenia gravis in two patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26418033" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Myasthenia gravis Lambert-Eaton overlap syndrome.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
